SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.98+1.1%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (8972)8/22/2003 3:37:05 PM
From: Miljenko Zuanic  Read Replies (1) of 52153
 
<<Generic biotechs are inevitable at some point, but they will have much less impact than current generics - much more expensive to produce and much harder to get approval - the JNJ Eprex problems may end up saving the biotechs from easy generics.>>

All depend how will pharmas act in next few years, and what will be challenged. Pharmas now have their own biologics manufacturing capability, and profit is very high relative to small molecules (where manufacturing shifted into Asia).

So, it is my view that biologics will be challenged and pharma will have success, here and there.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News